LSE - Delayed Quote USD

Roche Holding AG (0TDF.L)

39.79

+1.65

+(4.33%)

At close: 4:52:44 PM GMT+1

Roche strikes second Orionis deal to develop ‘molecular glues’ for cancer

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body of destructive proteins that are hard to target by other means.

BioPharma Dive 8 hours ago

ROG.SW
Lilly’s former small molecule head makes the leap to a rising biotech in obesity

Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.

Pharma Voice 11 hours ago

ROG.SW

LLY
$Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma$

Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

SOUTH SAN FRANCISCO, Calif., May 20, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) discussed the supplemental Biologics License Application (sBLA) for Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for autol

Business Wire yesterday

RHHBF

RHHBY

RHHVF
$Roche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma$

Roche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

Columvi is the first bispecific antibody to show a statistically significant and clinically meaningful 41% survival benefit in R/R DLBCL in the phase III STARGLO study1,2There is an urgent need for effective, immediately available therapies that are broadly accessible to people with transplant-ineligible R/R DLBCLThis first-of-its-kind Columvi combination could provide a much-needed, off-the-shelf and fixed-duration treatment option for patients who face poor prognosisThe clinical and disease ch

GlobeNewswire yesterday

RHHBF

RHHBY

RHHVF
Trump administration not backing down on Big Pharma pressure campaign

The pharmaceutical industry's patience is wearing thin with the Trump administration's pressure. But the administration doesn't care.

Yahoo Finance 4 days ago

LLY

RHHBF

RHHBY
Trump Trade: Trump asks Apple to stop building iPhone plants in India

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: IPHONE PLANTS: President Donald Trump is asking Apple (AAPL) CEO Tim Cook to stop building plants in India to make devices for the U.S., and is pushing for the iPhone maker to add domestic production, Bloomberg’s Jordan Fabian and Sankalp Phartiyal report. Apple plans to import most of the iPhone

TipRanks 5 days ago

RHHBF

RHHBY

RHHVF
FDA approves Roche’s MET protein expression detecting assay for NSQ-NSCLC

Results from the LUMINOSITY study indicated that those with high c-Met protein expression achieved a 35% ORR.

Medical Device Network 6 days ago

ROG.SW

ABBV
Roche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis

The VENTANA MET (SP44) RxDx Assay detects the MET (also known as c-Met) protein, which is over-expressed in some patients with non-squamous non-small cell lung cancer (NSQ-NSCLC).The MET protein serves as a predictive biomarker for the likelihood of a patient’s response to c-Met-targeted therapy.1As the leader in companion diagnostics, Roche’s broad CDx portfolio helps enable informed clinical decisions and improved patient outcomes. Basel, 14 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announ

GlobeNewswire 6 days ago

RHHBF

RHHBY

RHHVF
Q1 2025 Lineage Cell Therapeutics Inc Earnings Call

Q1 2025 Lineage Cell Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 7 days ago

LCTX

ROG.SW
Roche says Trump's drug price order threatens its $50 billion US investment plans

U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion investment in the United States, the company said on Wednesday. Trump's order, signed on Monday, directs drugmakers to lower prices of brand-name medicines to align with those in other wealthy nations. "Should the proposed EO (Executive Order) go into effect, Roche's ability to fund the significant investments previously announced in the U.S. will be in question," the company said in a statement.

Reuters 7 days ago

ROG.SW
Roche warns Trump's drug price order puts US investment at risk

Swiss pharma company Roche (ROG.SW, RHHBY) is warning that its investment into the US could be at risk due to President Trump's executive order calling for reductions in drug prices. Yahoo Finance senior health reporter Anjalee Khemlani shares more of the details. Catch Bernstein senior analyst Courtney Breen explain to Yahoo Finance why Trump's order is part request and part threat to drugmakers. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 7 days ago

RHHBF

RHHBY

RHHVF
Roche reports final overall survival outcomes from breast cancer treatment trial

The results showed a 17% decrease in mortality risk among subjects who underwent the Perjeta-based regimen.

Clinical Trials Arena 7 days ago

ROG.SW
Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%

Roche Holdings AG (OTC:RHHBY) on Tuesday released statistically significant final overall survival (OS) results from the phase III APHINITY study in people with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer. After ten years, the risk of death was reduced by 17% for people treated with Perjeta (pertuzumab), Herceptin (trastuzumab), and chemotherapy (the Perjeta-based regimen) for a year as post-surgery (adjuvant) treatment, compared with individuals who receiv

Benzinga 7 days ago

ROG.SW
RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US

Roche plans to invest over $700 million in setting up a new plant in North Carolina and up to $550 million in expanding its Indianapolis diagnostics hub.

Zacks 8 days ago

ROG.SW

LLY

NVS
Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer

SOUTH SAN FRANCISCO, Calif., May 13, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation, announced today statistically significant final overall survival (OS) results from the Phase III APHINITY study in people with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer. After ten years, the risk of death was reduced by 17% f

Business Wire 8 days ago

RHHBF

RHHBY

RHHVF
Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer

Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta® (pertuzumab) to Herceptin® (trastuzumab) and chemotherapy121% reduction in the risk of death was seen in the pre-specified subgroup of people with lymph node-positive disease1Data to be presented as a late-breaking abstract at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Congress Basel, 13 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), the Breast I

GlobeNewswire 8 days ago

RHHBF

RHHBY

RHHVF
Roche plans $700m manufacturing plant in the US

The new site will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines.

Pharmaceutical Technology 9 days ago

ROG.SW
Roche plans $550M expansion of Indianapolis site to manufacture CGMs

Roche Diagnostics plans to produce glucose monitors at the site within three years and prepare for future generations of its sensors.

MedTech Dive 9 days ago

ROG.SW
Roche announces $550 million investment to expand its Indianapolis diagnostics manufacturing hub

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it plans to invest up to $550 million in its Diagnostics site in Indianapolis by 2030. The site will become a major hub for the manufacturing of Roche's continuous glucose monitoring (CGM) systems – marking a new milestone in Roche's long history of revolutionizing healthcare across the globe.

PR Newswire 9 days ago

RHHBF

RHHBY

RHHVF
Roche boosts US presence with new $700 million North Carolina facility

The new facility, based in Holly Springs, North Carolina, will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines. Separately, Roche also announced plans to invest up to $550 million in its diagnostics site in Indianapolis by 2030, to manufacture continuous glucose monitoring systems.

Reuters 9 days ago

ROG.SW

Performance Overview

Return	0TDF.L	MSCI WORLD (^990100-USD-STRD)
YTD	+13.62%	+3.41%
1-Year	+20.47%	+10.18%
3-Year	--	+44.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Roche Holding AG (0TDF.L)

Roche strikes second Orionis deal to develop ‘molecular glues’ for cancer

Lilly’s former small molecule head makes the leap to a rising biotech in obesity

Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Roche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

Trump administration not backing down on Big Pharma pressure campaign

Trump Trade: Trump asks Apple to stop building iPhone plants in India

FDA approves Roche’s MET protein expression detecting assay for NSQ-NSCLC

Roche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis

Q1 2025 Lineage Cell Therapeutics Inc Earnings Call

Roche says Trump's drug price order threatens its $50 billion US investment plans

Roche warns Trump's drug price order puts US investment at risk

Roche reports final overall survival outcomes from breast cancer treatment trial

Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%

RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US

Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer

Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer

Roche plans $700m manufacturing plant in the US

Roche plans $550M expansion of Indianapolis site to manufacture CGMs

Roche announces $550 million investment to expand its Indianapolis diagnostics manufacturing hub

Roche boosts US presence with new $700 million North Carolina facility

Performance Overview